Reports Q2 revenue $617.4M, consensus $585.02M. “The second quarter clearly demonstrated Alkermes’ strong execution against our strategic priorities. We generated double-digit growth of our proprietary commercial products, advanced our development pipeline, and progressed the planned separation of our oncology business,” said Richard Pops, CEO. “As we enter the second half of the year, we are well positioned to continue to make meaningful progress across the business and drive shareholder value”.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ALKS:
- ALKS Upcoming Earnings Report: What to Expect?
- Alkermes shareholders re-elect all seven company director nominees
- Alkermes shareholders re-elect all company directors, Reuters reports
- Sarissa: Add Schlesinger to Alkermes board and ‘withhold’ Richard Gaynor
- Alkermes recently-appointed directors issue open letter to shareholders